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Abstract 
 
Subject numbers in neuroreceptor imaging studies of antipsychotic treatment in 
schizophrenia are generally insufficient to directly test the relationship of regional D2/D3 
and 5HT2A receptor binding to clinical efficacy. We selected positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) studies 
of antipsychotic dose vs. occupancy at both temporal cortex and striatal D2/D3 receptors.  
We selected corresponding SPECT and PET studies of 5HT2A receptor occupancy. We 
also selected randomized double blind clinical trials of antipsychotics, where patients 
were treated with randomly assigned fixed doses. For each antipsychotic drug, we 
compared the optimum effective antipsychotic dose with the dose inducing maximal 
occupancy of D2/D3 receptors in striatum, and in temporal cortex as well as at 5HT2A 
receptors. Both first- and second-generation antipsychotic drugs (FGA, SGA) produced 
high temporal cortex D2/D3 occupancy. Only FGA produced high striatal D2/D3 receptor 
occupancy. The clinically effective dose showed correlation with doses inducing maximal 
dopamine D2/D3 receptor occupancy both in striatum and in temporal cortex, the 
strongest correlation being with temporal cortex binding. EPSE were primarily related 
to striatal D2/D3 receptor occupancy. There was no correlation between 5HT2A 
occupancy and clinically effective dose. We conclude that cortical dopamine D2/D3 
receptor occupancy is involved in antipsychotic efficacy, with striatal D2/D3 occupancy 
having a likely therapeutic role whilst also inducing EPSE. We found no evidence for 
5HT2A blockade involvement in antipsychotic action, although we cannot exclude this 
possibility.  
 
Key words: Schizophrenia, antipsychotic, efficacy, limbic selectivity, EPSE, SPECT 
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Introduction 
Cortical dopamine D2 receptors have been hypothesized to be a common site of action for 
both first-generation (typical) antipsychotics (FGAs) and second-generation (atypical) 
antipsychotics (SGAs).1 The antagonism of 5HT2a receptors has also been hypothesized to 
play a critical component in SGA therapeutic action.2 Positron Emission Tomography (PET) 
and Single Photon Emission Computed Tomography (SPECT) allow the in vivo imaging of 
regional antipsychotic medication binding to receptor subtypes to explore the relationship of 
receptor binding to efficacy and side effects in living schizophrenic patients. These studies are 
low throughput, high cost and are highly labour intensive. Consequently sample sizes are 
usually too small to permit extensive analyses of receptor occupancy versus drug efficacy.  
 
Seeman and Snyder noted a striking correlation between the dose of an antipsychotic to 
produce D2 receptor occupancy in rodent brain tissue and the clinically effective dose.
3, 4 We 
decided to use a similar method, pooling original patient data from multiple centres (total 
n=139), and comparing the clinically effective dose for different antipsychotic drugs, with the 
dose required for each drug to induce maximal occupancy at dopamine receptors in striatum 
and temporal cortex, as well as in 5HT2a receptors. Through this approach, we have been able 
to explore the role of D2/D3 binding in striatum and temporal cortex plus 5HT2a binding on 
clinical efficacy. 
 
Methods 
Identification and selection of regional dose:occupancy studies 
Medline and PubMed were searched to identify all PET or SPECT studies examining 
dopamine and/or serotonin receptor occupancy of FGAs and SGAs, using the keywords 
“antipsychotic”, “occupancy”, “dopamine”, “serotonin” and “emission tomography”. We 
selected studies in which D2/D3 receptor availability was estimated in the same patient in both 
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striatum and temporal cortex, and in which patients were in steady state on an antipsychotic 
drug (chronic dosing). These criteria were designed to minimize any variation in apparent 
receptor occupancy due to differences in ligand affinity for receptor subtypes, inter-subject 
variability of receptor expression and differences in drug dose.  
 
One hundred and thirty nine studies were identified using our Medline search strategy. In 
total, 15 papers met our inclusion criteria for estimation of regional D2/D3 receptor occupancy 
with antipsychotic dose 5-19 and 3 papers met our inclusion criteria to analyze the relationship 
between antipsychotic dose and 5HT2a receptor occupancy.
20-22 Of the papers that were 
excluded, 78 papers reported striatal dopamine receptor occupancy only, 20 were review 
articles without detailed data. The remaining papers were excluded because they did not 
involve SPECT or PET radioligands, they were non-human studies, or they did not study 
D2/D3 or 5HT2a receptors.  
 
Consistency of imaging studies 
The methodology of all the selected imaging studies was broadly comparable, although there 
were two distinct designs of study to measure dopamine D2/D3 receptor binding with either 
simultaneous measurement of striatal and extrastriatal antipsychotic binding (single ligand 
studies) or measurement of striatal and extrastriatal antipsychotic binding in each subject with 
different tracers on separate occasions (dual ligand studies).  
 
In brief, patients with schizophrenia on a steady dose of antipsychotic medication and healthy 
age and sex-matched controls were recruited after informed consent was obtained. A 
radiolabelled ligand specific for the dopamine D2/D3 receptor ([
123I]epidepride, [18F]fallypride 
or [76Br]FLB-457 for single ligand studies or [11C]raclopride for striatal and [11C]FLB-457 for 
temporal D2 receptor binding in dual-ligand studies) or 5HT2a receptor ([
18F]setoperone) was 
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injected. Images were acquired sequentially after injection (on 2 separate occasions for the 
dual-ligand studies). Occupancy by the antipsychotic drug was estimated by comparison of 
receptor binding in drug treated patients with controls or unmedicated patients (after adequate 
washout time).  
 
Approximately 2/3 of the patients from the dopamine receptor occupancy studies were 
imaged using [123I]epidepride,11, 10, 5, 16, 13 whilst the rest were imaged using [18F]fallypride, 
[76Br]FLB-457 or [11C]raclopride and [11C]FLB-457 PET.6-9, 14, 15, 17-19 Almost all the patients 
(n=70) from the 5HT2a receptor occupancy studies were imaged with [
18F]setoperone,22, 21 
while 5 patients were imaged using [11C] N-methylspiperone.20 Table 1 shows the ligand 
used, the number of subjects in each study, and the method of receptor quantification for the 
dopamine receptor occupancy studies. 
 
Data extraction – imaging studies 
For each subject from the dopamine imaging studies, we extracted antipsychotic drug taken; 
dose of antipsychotic drug; estimated occupancy at striatal dopamine D2/D3 receptors; and 
estimated occupancy at temporal D2/D3 receptors, contacting the authors where necessary for 
additional data. From these data, we determined dose vs. occupancy on a per subject basis. 
We also calculated mean D2/D3 occupancy at striatum and temporal cortex for each drug. In 
one study,8 we were unable to match antipsychotic doses in a given subject with D2/D3 
receptor occupancy data for the same subject, and so we could use data from this study to 
calculate mean occupancies only. 
 
For the serotonin imaging studies, we extracted estimated mean occupancy of 5HT2a receptors 
at fixed doses of each antipsychotic drug. For striatal and temporal cortex D2/D3 receptor 
occupancy and for 5HT2a occupancy, we calculated the dose at which consistent maximal 
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occupancy occurred (ED95occ). As FGAs consistently showed significantly higher D2/D3 
receptor occupancy in striatum at doses imaged compared to SGAs (which had a mean striatal 
occupancy of 49%), it is possible that the ED95occ for FGAs (calculated from the doses 
imaged) may have meant that like was not being compared with like with respect to striatal 
D2/D3 receptor occupancy. Therefore, we also calculated the dose at which FGAs would be 
expected to achieve 49% striatal D2/D3 receptor occupancy. We used the slope of the 
significant linear correlation between FGA dose given to each individual patient, in 
haloperidol equivalents, and their individual striatal occupancy to estimate the dose necessary 
to achieve a mean striatal occupancy of 49% for FGAs. 
  
Identification and selection of dose:efficacy and dose:side-effect studies 
In order to calculate the dose-response curve for efficacy and extrapyramidal side effects 
(EPSE), we selected studies in which patients with schizophrenia were randomly assigned to 
placebo and to fixed doses (or dose ranges – at steady state) of second-generation 
antipsychotics and efficacy and EPSE assessed by double-blind techniques and included all 
such trials. The design is necessary for a valid assessment of dose response.  
 
For olanzapine we included two studies that performed dose ranging of acute patients: one 
assigning patients to placebo and a narrowly defined dose range of 52.5, 102.5, and 152.5 
mg/day of olanzapine,23 and the other assigning patients to placebo, 1mg and 10 mg/day of 
olanzapine.24 For risperidone, we used two large registrational studies, one from the United 
States 25 and one from Canada comparing patients to placebo 2, 4, 8, and 16 mg/day.26 For 
quetiapine, we used three fixed dose studies: One assigning patients to placebo, 75, 150, 300, 
450, and 600 mg/day quetiapine,27 the second assigning patients to placebo, low dose range (< 
250 mg/day), and high dose range (>250mg/day) quetiapine,28 and the third assigning patients 
to 400, 600 and 800 mg/day quetiapine.28 For sertindole, we used two studies: One comparing 
  
7 
7 
placebo to, 8, 12, and 20 mg/day sertindole and 4, 8, and 16 mg/day haloperidol,29  and 
another comparing sertindole to placebo, 8, 12, and 20 mg/day.30 For amisulpride, there was 
only one dose:response study that compared 100, 400, 800 and 1200 mg/day amisulpride, 
with no placebo group.31 Adjustment for the placebo effect in this study was made by 
extrapolating the placebo effect from other studies. For clozapine, there was again only one 
dose:response study comparing 100, 300 and 600mg/day.32 There was no placebo group, but 
during the washout phase, placebo treated patients deteriorated, so we used baseline period 
for an estimate of placebo response.  
 
Using higher doses than necessary can produce an increase in side effects but no greater 
increase in therapeutic benefit because the dose-response curve is sigmoidal. We calculated 
the optimal dose from the dose-response curve from the large random-assignment double-
blind fixed-dose clinical trials. We termed this the ED95 clinically effective dose (ED95eff), 
since it corresponded to the dose at which the drug is maximally effective for almost all the 
patients. The methodology of study identification, analysis, and for calculating dose-response 
has been previously described and more details about such calculations are reported in detail 
in our previous publication.33  
 
Analyses 
Comparison of regional receptor occupancy in different antipsychotic drugs 
We compared mean D2/D3 receptor occupancy in striatum, temporal cortex or their ratio in 
FGA versus SGA using unpaired student’s t-test with unequal variances.   
 
Relationship of Clinical Response to receptor occupancy 
We plotted the log of ED95eff (y-axis) against the log of ED95occ for D2/D3 receptor 
occupancy in the temporal cortex. As FGAs did not show comparable striatal D2/D3 receptor 
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occupancies to SGAs at doses imaged (discussed above), we plotted both the dose inducing 
maximal striatal D2/D3 receptor occupancy by FGAs, as well as the estimated FGA dose to 
achieve the same striatal occupancy as seen with SGAs (49%). We compared the correlations 
of efficacy vs. striatal or temporal cortex with a t-test for the difference between two 
correlations sharing a common variable 34. 
 
As the 5HT2A receptor occupancy studies did not always include doses equivalent to the 
ED95 efficacy (therapeutic doses), there were three dimensions to examine: the dose used to 
image, the level of 5HT2A occupancy at this dose, and the ED95eff (therapeutic dose). We 
plotted the range of doses imaged vs. 5HT2A occupancy with a line, and indicated the 
ED95eff for each drug using a separate marker.  
 
We examined the relationship between ED95occ for and ED95eff for 5HT2A occupancy and 
for striatal and temporal cortex D2/D3 receptor occupancy using Pearson’s product-moment 
correlation. 
 
Sensitivity Analysis 
Although our estimates of ED95eff were based on the evidence derived from the dose finding 
studies of each compound, there remained some uncertainty about the most effective clinical 
dose for some agents, e.g., the two dose-response studies of quetiapine yielded slightly 
different estimates, and opinion differs about the optimal dose of clozapine. In order to 
address these issues, we performed sensitivity analyses at 28 different doses (approximately 
four on each of the seven drugs) and correlated these to receptor occupancy. 
 
Relationship of EPSE to receptor occupancy 
We explored the EPSE risk of FGAs by correlating the doses (in haloperidol equivalents) in 
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the individual patients from the imaging studies with striatal and temporal receptor 
occupancy.  
 
Comparison of results using different ligands and different modeling methods 
SPECT and PET studies of occupancy can be divided into those using a single ligand to 
estimate binding in both striatal and cortical brain regions ([123I]epidepride, [18F]fallypride) 
and those using different ligands for each brain region ([11C]raclopride for striatum and 
[11C]FLB-457 for cortical brain regions). Analysis of binding is now usually estimated using 
the simplified reference tissue model (SRTM). Some earlier studies employed a simpler 
(ratio) method (see table 1). There has been some concern that different methods of 
measuring dopamine receptor occupancy may be affected by different imaging methods, or 
different methods of quantification of the radiotracer binding.35, 17, 36-38 In order to address 
these concerns, we included all studies using different methods of analysis in the meta-
analysis. We also analysed the differences in receptor occupancy reported by both single 
ligand and two ligand methods of imaging separately and then separately analysed the 
differences between the SRTM and ratio methods of binding estimation. 
 
To study the difference between the single- and the dual-ligand approach to determine 
occupancy, we used an ANOVA with drug (typical-atypical) and single versus dual-ligand as 
independent factors, and D2/D3 receptor occupancy of striatal or temporal cortex as the 
dependent variable without the interaction in the final model.  A similar ANOVA was done 
using drug and SRTM versus ratio method and an ANCOVA with single versus dual-ligand 
and SRTM versus ratio methods as covariants, to adjust the typical-atypical differences. 
 
Results 
First- and second-generation antipsychotic drugs and D2/D3 occupancy 
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FGAs (n=28) produced significantly higher striatal (74+/-SD=12%) occupancy than SGAs 
(n=115, 49+/-21%; t = 8.8,df=73.7,p< 4*10-13). Both FGAs and SGAs produced 70-80% 
D2/D3 occupancy in the temporal cortex, though FGAs had slightly higher cortical occupancy 
(77+/-12%) than SGAs (67+/-19%)(unpaired t-test, t=3.5,df=62.3,p=0.001) (Figure 1A). 
 
FGAs showed a significantly greater occupancy of striatal dopamine D2/D3 receptors (S/T 
ratio = 96%, SD=24%) than SGAs (S/T ratio = 74%, SD=35%; t=3.7,df=41,p<0.001). All 
SGAs showed greater differentiation between cortical and striatal D2/D3 binding within each 
subject than FGAs (amisulpride 36+/-15%; clozapine 17+/-16%; olanzapine 40+/-16 %; 
quetiapine 20+/-12; risperidone 26+/-7%; sertindole 16+/-10%, FGAs 5+/-17%). 
 
Correlation of clinically effective dose with receptor occupancy 
There was a high correlation of ED95eff with temporal cortex dopamine D2/D3 receptor 
ED95occ (r=0.95, n=7, p<0.001; see Figure 1B). A less strong correlation was also found 
between ED95eff and actual striatal dopamine D2/D3 receptor ED95occ (r=0.76, n=7, 
p=0.046; see Figure 1C; significance of  difference between r=0.95 and r=0.76: t=1.7, DF=4, 
p= .08). Substituting the FGA ED95occ with the dose required to achieve the same striatal 
occupancy as SGAs had no significant effect on the correlation (r=0.76, n=7, p=0.046). 
Interestingly, the correlation between the natural log of the antipsychotic doses was highly 
significant for both striatum and temporal cortex D2/D3 ED95occ vs. ED95eff, although 
temporal cortex still showed a slightly higher correlation (temporal cortex r=0.99, n=7, 
p<0.0001; striatum high FGA occupancy r=0.94, n=7, p<0.005; striatum same FGA 
occupancy as SGA r=0.86, n=7, p<0.05; significance of difference between r=0.99 and 
r=0.86: t=3.1,df=4, p=.02). The correlation between ED95eff and 5HT2a receptor ED95occ 
was not statistically significant (r=0.29, n=5, ns), partly because amisulpride produced no 
5HT2 blockade, but also because clozapine led to very high 5HT2A receptor occupancy at sub-
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therapeutic doses (see figure 1D). 
 
 
Sensitivity analysis 
The mean correlation (r) between ED95eff and temporal or the actual striatal D2/D3 receptor 
occupancy using 28 different dose schedules was r=0.98 for temporal cortex and r=0.69 for 
striatum. Thus the sensitivity analyses were consistent with the primary analysis. 
 
Antipsychotic propensity for EPSE and regional dopamine receptor occupancy:  
Doses of FGAs were moderate. Of the 28 subjects, 18 received haloperidol with an average 
dose of 9 mg/day, while most others received high potency FGAs. Only three subjects 
received doses of haloperidol over 12 mg/day. The FGA dose (in haloperidol equivalents) for 
each individual was significantly correlated with striatal D2/D3 receptor occupancy (r=0.59, 
df=22, p=0.004; p=0.004), but for temporal cortex D2/D3 receptor occupancy, this correlation 
was not significant (r=0.38, df=22, p=ns).  
 
Comparison of results using SRTM vs. ratio modeling 
The mean temporal cortex D2/D3 occupancy estimated was 61% by the ratio method and 78% 
with SRTM, a difference of 14.6%  (95% CI:  to 21, F=21.3, F=8.8: df=1,127: p=0,004). 
However the ratio and SRTM methods did not produce a significant alternation in striatal 
occupancy. (F = 1.5, df=1,127: ns). Importantly the SRTM or ratio method did not alter the 
difference between typical versus atypical occupancy. The interaction of   the SRTM/Ratio 
method and typical/atypical drug was essentially zero for both striatal (F = 0.0, df=1,127:ns) 
and temporal cortex (F= 0.1,df=1,127:ns). 
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Comparison of results using single vs. dual ligands 
The ANOVA showed a significant difference between the single- and the dual-ligand method 
used in both brain areas (striatal and temporal). The single-ligand studies reported 18% (95% 
CI: 10% to 25%) lower striatal D2/D3 receptor binding than the dual-ligand studies (F = 22; df 
= 1,128; p =0.000007). In the temporal cortex the single-ligand studies found 13% (95% CI: 
6% to 21%) higher D2/D3 receptor occupancy than the dual-ligand studies (F=13; df = 1,128; 
p=0.0006). The interaction of FGA-SGA used with single- versus dual-ligand method was not 
significant for striatal (F=1.5; df=1,128; NS) or temporal cortex (F=0.7; df=1,128; NS). 
 
After adjustment by ANCOVA with single/dual ligand and SRTM/ratio as covariate, the 
striatal occupancy was 74% (95% CI: 66% to 82%) for typical antipsychotics, and  47% for 
atypicals (95% CI: 44% to 54%), a difference of 27% (18% to 36%), and statistically 
significant ( F= 37, df=1, 127, p= 0.00000005). 
 
Discussion 
This is the first meta-analysis pooling original patient PET and SPECT receptor imaging data 
to better understand the mode of action of antipsychotic drugs in vivo in patients with 
schizophrenia. We found that both SGAs and FGAs produce high (70-80%) D2/D3 occupancy 
in the temporal cortex, but that only the FGAs produce high D2/D3 receptor occupancy in the 
striatum. The clinically effective dose (ED95eff) showed a highly significant linear 
correlation with the dose required to induce maximal temporal cortex D2/D3 receptor 
occupancy. There was a less strong, but still significant, linear correlation with the dose 
required to induce maximal striatal dopamine D2/D3 receptor occupancy, whether actual doses 
imaged, or estimated FGA dose required to produce the same striatal occupancy as SGAs 
were used. This suggests that the temporal cortex and striatum are both possible targets for 
antipsychotic efficacy. 
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We found that the dose of FGA was linearly related to striatal occupancy, and not to temporal 
cortical occupancy. As propensity to induce EPSE increases with increasing FGA dose, this 
suggests that EPSE are more closely related to dopamine receptor occupancy in striatum than 
in temporal cortex. 
 
The absence of a significant correlation between efficacy and 5HT2a binding, and the fact that 
atypicality is possible without significant 5HT2A binding (amisulpride), suggests that 5HT2a 
binding is not a central component of either the therapeutic or EPSE components of SGA 
antipsychotic action, although we cannot completely exclude the possibility that 5HT2A 
blockade is important in the functionality of some antipsychotic drugs, since high 5HT2A 
receptor occupancy at doses used therapeutically is a feature of 4 out of the 5 SGAs 
investigated in this study.  
 
Methodological consideration 
Assumptions about drug mechanisms 
In grouping drugs together (SGA vs. FGA) we have made the assumption that these drugs 
behave similarly to others in the same group. This is not necessarily the case since both FGAs 
and SGAs have widely varying action at other receptor subtypes besides dopamine D2 
receptors. It should be noted that the FGAs imaged were either haloperidol or other high 
potency antipsychotic drugs. If lower potency FGAs had been imaged, it is possible that the 
difference between FGAs and SGAs in terms of striatal and cortical D2 receptor occupancy 
would not have been so marked. 
  
Dose:efficacy and Dose:occupancy estimation 
The ideal method of estimating the relationship of clinical efficacy and side effect profile to 
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receptor occupancy is to assess dose-response curves and imaging in the same patient. In 
order to achieve this, it would be necessary to evaluate large samples of patients who are in an 
episode of acute psychotic illness at baseline, and then again for 3-6 weeks treatment with 
different antipsychotic drugs. Patients should also be randomly assigned to multiple fixed 
doses on the log-linear part of the dose-response curve. Three such studies have yielded 
important results, but they examined striatal D2/D3 receptor occupancy only.
39-41 We feel that 
such designs have considerable advantages in that they allow the assessment of dose-response 
for efficacy and extrapyramidal side effects and measurement of receptor occupancy in the 
same subject. 
 
Since data employing antipsychotic dosing and simultaneous striatal and extrastriatal D2/D3 
receptor imaging in the same patient were not available, we used data from well-designed 
clinical trials for determination of ED95 for clinical efficacy and EPSE in order to combine 
with the ED95 receptor occupancy results from the SPECT and PET imaging studies. Patients 
in the dosing studies were therefore not the same who underwent scanning.  It is possible that 
the doses leading to 95% clinical effect and EPSE could differ somewhat between the 
populations of the dosing studies and the scanning studies, which would lead to a degree of 
inaccuracy in the correlation of clinical effect and EPSE with dopamine receptor occupancy. 
As the patients in the dosing studies were similar to those in the scanning studies, in that they 
were chronic patients with schizophrenia on long-term antipsychotic treatment, we believe 
that this effect should be minimal. Sensitivity analysis shows that the correlation of D2/D3 
occupancy and clinical dose was consistent over a wide choice of clinical doses. 
 
Scanning and modeling methods 
In keeping with previous reports, we found that single-ligand studies tended to report lower 
striatal occupancy regardless of modeling method used, and that dual-ligand studies  
  
15 
15 
(employing [11C]FLB-457) reported lower temporal cortex occupancy. One possible reason 
for this is given by the suggestion that [11C]FLB-457 might not reach equilibrium within the 
maximum scan time possible with an [11C] labeled tracer.35 [11C]FLB-457 has also been 
shown to have significant binding to D2 receptors in the cerebellum and, as this region is used 
as a reference region in SRTM analysis (assumed to have no significant binding),  measures 
of cortical D2 receptor occupancy might be significantly underestimated using this ligand.
38 
On the other hand, the use of a single high affinity ligand to estimate binding in both striatum 
and temporal cortex might underestimate striatal occupancy.36 
 
We found a difference between single- and dual-ligand methods, but no interaction between 
method and drug administered, indicating that the difference in receptor occupancy of typical 
and atypical drugs occurs with both methods to an approximately equal degree. We also 
found that method of analysis (ratio vs. SRTM) made no significant difference to the results. 
 
It should be noted that interpretation of drug binding studies using PET and SPECT imaging 
is complex, since changes in ligand binding can be affected by the affinity of the ligand, the 
affinity of the drug and the level of endogenous dopamine in different brain regions.42 
Whether the higher temporal cortex binding by SGAs detected by the single-ligand method is 
actually a true increase in receptor occupancy by antipsychotic drug, or alternatively, a 
complex interaction between the affinity state of the D2/D3 receptor, endogenous dopamine, 
antipsychotic drug affinity and ligand affinity for the receptor is currently not clear. It is 
possible that the finding of regional preferential occupancy of antipsychotic drugs is an 
artefact of the imaging method used. However, the fact remains that PET or SPECT studies 
employing a single ligand are able to distinguish between high potency FGAs and SGAs 
based on the ratio between striatal and temporal occupancy. 
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Plotting occupancy vs. clinical dose 
In striatum, FGAs had high occupancy at all doses imaged, whereas SGAs had a lower D2 
receptor occupancy over all doses. This posed some difficulty in plotting 95% D2 receptor 
occupancy for SGAs, but since occupancy was stable over the dose ranges imaged, we 
assumed that the imaged occupancy value was the maximum obtainable in the striatum by 
SGAs, and calculated ED95 occupancy on this basis. It is possible that the lower correlation 
between striatal D2 receptor occupancy and clinically effective dose may have been driven by 
this difference between SGAs and FGAs. When the dose of typical to produce the same 
occupancy is plotted, the relationship is clearly non-linear. This, however, is a projected dose 
from the individual patient data. We caution the reader to keep this in mind. 
 
Cortical dopamine receptor binding 
It has long been suspected that mesolimbic dopamine circuits may be of more relevance to the 
symptoms of schizophrenia than the nigrostriatal pathway,43, 44 and structural and functional 
changes in hippocampus and temporal cortex have been some of the most robust findings in 
the illness.45-47 Other brain regions have been implicated in schizophrenia however, 
particularly dorsolateral prefrontal cortex, anterior cingulate and thalamus,48-50 and it is likely 
that pathological changes in schizophrenia affect multiple cortical and subcortical brain 
regions. The results from the present meta-analysis support the hypothesis that cortical D2/D3 
receptors are likely to be an important site of antipsychotic action,1 but this does not exclude 
the involvement of other brain regions that have not been studied. 
 
One small but well designed study included in this paper found a significant relationship 
between striatal D2 receptor binding and reduction in psychotic symptoms, but found a less 
strong correlation with D2 binding in cortical brain regions.
19 The less strong correlation may 
have arisen because dopamine receptor density in temporal cortex is low relative to striatum 
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and so extrastriatal measurements tend to have lower signal to noise ratio than striatal 
measurements, requiring greater numbers to find a significant correlation. It should be noted 
that we also found a correlation between antipsychotic efficacy and striatal D2/D3 receptor 
occupancy and so cannot exclude the involvement of striatal D2/D3 receptor blockade in 
antipsychotic action. 
 
Sub-striatal regions  
It is possible that, in addition to inducing extrapyramidal side effects, dopamine receptor 
occupancy in striatum may have therapeutic effects. This might arise through action at sub-
regions of the striatum. The striatum is split into three functionally distinct units, which blend 
into different anatomical regions. The putamen is primarily sensori-motor in function, the 
caudate performs more cognitive and associative roles, while the ventral parts of the striatum 
are involved in emotional processing, salience and reward.51, 52 Blockade of dopamine 
receptors in caudate and ventral striatum might, therefore, be expected to also be involved in 
antipsychotic efficacy and so D2/D3 receptor binding in these striatal sub-regions would be 
expected to correlate with antipsychotic efficacy. Two pharmacologically distinct SGAs 
(amisulpride and risperidone) both show selective occupancy of D2/D3 receptors in the head 
of caudate over the putamen,53 suggesting that reduced D2/D3 receptor binding in the putamen 
alone may be the distinguishing feature of atypical antipsychotic drugs. 
 
As very few of the papers included in this meta-analysis examined subregions of the striatum, 
it is possible that the correlation between antipsychotic efficacy and striatal occupancy may 
have been driven through dopamine receptor occupancy in caudate or ventral striatum. New 
developments in SPECT and PET resolution, allowing greater distinction between 
nigrostriatal, mesolimbic and mesocortical striatal regions, will help to further elucidate the 
importance of sub-regional binding of antipsychotic drugs for efficacy and side-effect profile. 
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Conclusions 
This novel meta-analysis of original patient data provides the first human in vivo evidence 
that the clinically efficacious dose of antipsychotic drugs is related to dopamine D2/D3 
receptor occupancy in cortical brain regions. D2/D3 binding in sub-regions of the striatum is 
also likely to be therapeutically important. The data suggest that extrapyramidal side effects 
are primarily related to striatal, and not cortical, D2/D3 occupancy. 5HT2A occupancy does not 
appear to be a central component of SGA efficacy or EPSE profile.  
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Table 1:  Papers included in meta-analysis. Antipsychotic, ligand and analysis method 
used (ratio or SRTM – simple reference tissue model) are displayed. Number of subjects 
in each study (n) are shown. * Data from 3 extra previously unpublished subjects on 
clozapine from Pilowsky et al. 2007 were included. 5 subjects in Bigliani et al. 1999 
overlapped with Pilowsky et al. 2007 and were not included twice. 5 subjects from 
Xiberas et al 2002a overlapped with Xiberas et al 2002b, and were not included twice, 
and one further subject from Xiberas et al 2002a had almost undetectable plasma blood 
levels and 0% dopamine receptor occupancy, and was not included in the analysis. 
Although included for the group comparison of FGA vs. SGA occupancy, subjects from 
Kessler et al. 2005 were not used for the within subject analysis of striatal vs. temporal 
cortex occupancy as individual dose:occupancy data were not available. 
 
  
20 
20 
Figure 1 A: dopamine D2/D3 receptor occupancy (error bars=SD) by FGAs (n=28) and SGAs 
(n=111) in striatum and temporal cortex. FGAs (n=28) produced significantly higher striatal 
(74+/-SD=12%) occupancy than SGAs (n=115, 49+/-19%; t = 8.8,df=73.7, p< 4*10-13). B: 
Correlation of ED95 clinically effective dose vs. ED95 temporal cortex D2/D3 receptor 
occupancy by antipsychotic drugs (p<0.001). C: Correlation of ED95 clinically effective dose 
vs. ED95 striatal D2/D3 receptor occupancy by antipsychotic drugs (p<0.05). D: Plot of 
5HT2A ED95 clinically effective dose (diamond), ED95occ (cross) and doses actually imaged 
in each subject indicated as a broken line showing the upper to lower range vs. 5HT2a receptor 
occupancy (%) by antipsychotic drugs. 
A       B 
 
 
 
 
 
 
C       D 
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